Systematic review of available evidence on 11 high-priced inpatient orphan drugs

10.1186/1750-1172-8-124

Saved in:

Bibliographic Details
Main Authors:	Kanters, T.A, De Sonneville-Koedoot, C, Redekop, W.K, Hakkaart, L
Other Authors:	SAW SWEE HOCK SCHOOL OF PUBLIC HEALTH
Format:	Article
Published:	2020
Subjects:	agalsidase alfa agalsidase beta alemtuzumab canakinumab clofarabine eculizumab fludarabine galsulfase iduronate 2 sulfatase laronidase ofatumumab orphan drug recombinant glucan 1,4 alpha glucosidase trabectedin acute lymphoblastic leukemia article case study chronic lymphatic leukemia CINCA syndrome clinical effectiveness cost effectiveness analysis cost utility analysis drug approval drug cost evidence based medicine Fabry disease hospital patient human mucopolysaccharidosis observational study paroxysmal nocturnal hemoglobinuria quality adjusted life year quasi experimental study soft tissue sarcoma systematic review cost benefit analysis drug manufacture economics Netherlands randomized controlled trial (topic) Rare Diseases standards Cost-Benefit Analysis Humans Inpatients Orphan Drug Production Randomized Controlled Trials as Topic
Online Access:	https://scholarbank.nus.edu.sg/handle/10635/181805
Tags:	Add Tag No Tags, Be the first to tag this record!
Institution:	National University of Singapore

id	sg-nus-scholar.10635-181805
record_format	dspace
spelling	sg-nus-scholar.10635-1818052023-10-31T21:37:35Z Systematic review of available evidence on 11 high-priced inpatient orphan drugs Kanters, T.A De Sonneville-Koedoot, C Redekop, W.K Hakkaart, L SAW SWEE HOCK SCHOOL OF PUBLIC HEALTH agalsidase alfa agalsidase beta alemtuzumab canakinumab clofarabine eculizumab fludarabine galsulfase iduronate 2 sulfatase laronidase ofatumumab orphan drug recombinant glucan 1,4 alpha glucosidase trabectedin acute lymphoblastic leukemia article case study chronic lymphatic leukemia CINCA syndrome clinical effectiveness cost effectiveness analysis cost utility analysis drug approval drug cost evidence based medicine Fabry disease hospital patient human mucopolysaccharidosis observational study paroxysmal nocturnal hemoglobinuria quality adjusted life year quasi experimental study soft tissue sarcoma systematic review cost benefit analysis drug manufacture economics Netherlands randomized controlled trial (topic) Rare Diseases standards Cost-Benefit Analysis Humans Inpatients Netherlands Orphan Drug Production Randomized Controlled Trials as Topic Rare Diseases 10.1186/1750-1172-8-124 Orphanet Journal of Rare Diseases 8 1 124 2020-10-28T07:19:30Z 2020-10-28T07:19:30Z 2013 Article Kanters, T.A, De Sonneville-Koedoot, C, Redekop, W.K, Hakkaart, L (2013). Systematic review of available evidence on 11 high-priced inpatient orphan drugs. Orphanet Journal of Rare Diseases 8 (1) : 124. ScholarBank@NUS Repository. https://doi.org/10.1186/1750-1172-8-124 17501172 https://scholarbank.nus.edu.sg/handle/10635/181805 Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/ Unpaywall 20201031
institution	National University of Singapore
building	NUS Library
continent	Asia
country	Singapore Singapore
content_provider	NUS Library
collection	ScholarBank@NUS
topic	agalsidase alfa agalsidase beta alemtuzumab canakinumab clofarabine eculizumab fludarabine galsulfase iduronate 2 sulfatase laronidase ofatumumab orphan drug recombinant glucan 1,4 alpha glucosidase trabectedin acute lymphoblastic leukemia article case study chronic lymphatic leukemia CINCA syndrome clinical effectiveness cost effectiveness analysis cost utility analysis drug approval drug cost evidence based medicine Fabry disease hospital patient human mucopolysaccharidosis observational study paroxysmal nocturnal hemoglobinuria quality adjusted life year quasi experimental study soft tissue sarcoma systematic review cost benefit analysis drug manufacture economics Netherlands randomized controlled trial (topic) Rare Diseases standards Cost-Benefit Analysis Humans Inpatients Netherlands Orphan Drug Production Randomized Controlled Trials as Topic Rare Diseases
spellingShingle	agalsidase alfa agalsidase beta alemtuzumab canakinumab clofarabine eculizumab fludarabine galsulfase iduronate 2 sulfatase laronidase ofatumumab orphan drug recombinant glucan 1,4 alpha glucosidase trabectedin acute lymphoblastic leukemia article case study chronic lymphatic leukemia CINCA syndrome clinical effectiveness cost effectiveness analysis cost utility analysis drug approval drug cost evidence based medicine Fabry disease hospital patient human mucopolysaccharidosis observational study paroxysmal nocturnal hemoglobinuria quality adjusted life year quasi experimental study soft tissue sarcoma systematic review cost benefit analysis drug manufacture economics Netherlands randomized controlled trial (topic) Rare Diseases standards Cost-Benefit Analysis Humans Inpatients Netherlands Orphan Drug Production Randomized Controlled Trials as Topic Rare Diseases Kanters, T.A De Sonneville-Koedoot, C Redekop, W.K Hakkaart, L Systematic review of available evidence on 11 high-priced inpatient orphan drugs
description	10.1186/1750-1172-8-124
author2	SAW SWEE HOCK SCHOOL OF PUBLIC HEALTH
author_facet	SAW SWEE HOCK SCHOOL OF PUBLIC HEALTH Kanters, T.A De Sonneville-Koedoot, C Redekop, W.K Hakkaart, L
format	Article
author	Kanters, T.A De Sonneville-Koedoot, C Redekop, W.K Hakkaart, L
author_sort	Kanters, T.A
title	Systematic review of available evidence on 11 high-priced inpatient orphan drugs
title_short	Systematic review of available evidence on 11 high-priced inpatient orphan drugs
title_full	Systematic review of available evidence on 11 high-priced inpatient orphan drugs
title_fullStr	Systematic review of available evidence on 11 high-priced inpatient orphan drugs
title_full_unstemmed	Systematic review of available evidence on 11 high-priced inpatient orphan drugs
title_sort	systematic review of available evidence on 11 high-priced inpatient orphan drugs
publishDate	2020
url	https://scholarbank.nus.edu.sg/handle/10635/181805
_version_	1781792587895537664

Systematic review of available evidence on 11 high-priced inpatient orphan drugs

Similar Items